| Registry of Patients Having Received oNKord® (NCT05290662) | Glycostem Therapeutics BV | 2022-06-14 |
| A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure (NCT05285813) | M.D. Anderson Cancer Center | 2022-05-06 |
| Diagnosis and Treatment of Periodontal Disease in Patients With AML (NCT04530695) | Masonic Cancer Center, University of Minnesota | 2022-05-01 |
| Universal CAR-γδT Cell Injection in the AML Patients (NCT05388305) | Hebei Senlang Biotechnology Inc., Ltd. | 2022-04-20 |
| Cardioprotection in AML (NCT04977180) | University of Virginia | 2022-03-04 |
| GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG (NCT05153226) | DKMS gemeinnützige GmbH | 2022-03-02 |
| Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies (NCT05239689) | Zhejiang University | 2022-02-28 |
| Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies (NCT05252572) | Zhejiang University | 2022-02-28 |
| Study to Assess an Interphase Cycle With Flotetuzumab. (NCT05063123) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2022-01-01 |
| Drug-screening in AML at Relapse for Targeted Treatment (NCT05732688) | Insel Gruppe AG, University Hospital Bern | 2022-01-01 |
| NK Cell Therapy for AML (NCT05256277) | Zhejiang University | 2021-12-28 |
| Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis (NCT05062278) | Hospital Universitario Dr. Jose E. Gonzalez | 2021-07-26 |
| A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors (NCT04686682) | Jacobio Pharmaceuticals Co., Ltd. | 2021-05-07 |
| Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS (NCT05175508) | The First Affiliated Hospital of Soochow University | 2021-05-01 |
| A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML (NCT04730258) | Treadwell Therapeutics, Inc | 2021-04-16 |
| Donor-derived CAR-T Cells in the Treatment of AML Patients (NCT04766840) | Beijing Immunochina Medical Science & Technology Co., Ltd. | 2021-03-01 |
| The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission (NCT05339204) | National Research Center for Hematology, Russia | 2021-02-01 |
| Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation (NCT04796441) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-12-16 |
| A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS (NCT04358393) | Ascentage Pharma Group Inc. | 2020-12-04 |
| NK Cell Therapy Recurrent/Refractory Elderly AML (NCT04599452) | The Second Hospital of Shandong University | 2020-12-01 |
| Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (NCT04644016) | Memorial Sloan Kettering Cancer Center | 2020-11-20 |
| Haplo Peripheral Blood Sct In GVHD Prevention (NCT04473911) | Zachariah Michael DeFilipp | 2020-08-14 |
| Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia. (NCT04425655) | University of California, San Diego | 2020-08-05 |
| Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML (NCT04365179) | Immune System Key Ltd | 2020-06-18 |
| A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (NCT05933070) | Inmune Bio, Inc. | 2020-06-15 |
| Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia (NCT04128020) | Sherif Farag | 2019-10-10 |
| Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib (NCT04079738) | H Scott Boswell | 2019-09-20 |
| Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML (NCT04061239) | GWT-TUD GmbH | 2019-08-19 |
| CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS (NCT04017546) | Cyclacel Pharmaceuticals, Inc. | 2019-08-02 |
| Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia (NCT03844997) | Sudipto Mukherjee, MD, PhD, MPH | 2019-06-06 |
| Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML) (NCT04187495) | Maxinovel Pty., Ltd. | 2019-04-16 |
| A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant (NCT03739502) | University of Rochester | 2019-02-28 |
| Epacadostat, Cladribine and Cytarabine (ECC) in AML (NCT03491579) | Insel Gruppe AG, University Hospital Bern | 2018-12-01 |
| Epacadostat, Idarubicin and Cytarabine (EIC) in AML (NCT03444649) | Insel Gruppe AG, University Hospital Bern | 2018-09-01 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies (NCT03465540) | Amgen | 2018-08-17 |
| Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T) (NCT03585517) | Beijing Immunochina Medical Science & Technology Co., Ltd. | 2018-07-21 |
| Italian Non-Interventional Study of FLT3 Mutated AML Patients (NCT03547258) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2018-07-18 |
| Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS (NCT03459859) | Justin Watts, MD | 2018-05-21 |
| Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS (NCT03855371) | Ruijin Hospital | 2018-01-10 |
| Haploidentical Donor vs mMUD in Hematological Malignancies (NCT03275636) | DKMS gemeinnützige GmbH | 2018-01-01 |
| The Mutation Profile and Prognosis in AML With IDH1/2 Mutation (NCT07004816) | Institute of Hematology & Blood Diseases Hospital, China | 2017-12-21 |
| Ascorbic Acid Levels in MDS, AML, and CMML Patients (NCT03526666) | Van Andel Research Institute | 2017-11-01 |
| Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD (NCT03135054) | The University of Hong Kong | 2017-10-01 |
| Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia (NCT03118466) | Massachusetts General Hospital | 2017-09-25 |
| iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML (NCT03138395) | University of Florida | 2017-09-15 |
| Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD (NCT03170895) | The University of Hong Kong | 2017-07-01 |
| CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia (NCT02995655) | Washington University School of Medicine | 2017-04-07 |
| Familial Investigations of Childhood Cancer Predisposition (NCT03050268) | St. Jude Children's Research Hospital | 2017-04-06 |
| Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML (NCT03021330) | Institute of Hematology & Blood Diseases Hospital, China | 2017-02-08 |
| Efficacy of Decitabine in Clearance of MRD (NCT03021395) | Institute of Hematology & Blood Diseases Hospital, China | 2017-02-08 |
| Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia (NCT03031249) | Institute of Hematology & Blood Diseases Hospital, China | 2017-02-08 |
| Efficacy and Safety of Chidamide in CBF Leukemia (NCT03031262) | Institute of Hematology & Blood Diseases Hospital, China | 2017-02-08 |
| Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia (NCT02905994) | Massachusetts General Hospital | 2016-09-01 |
| Pre-emptive Immunomodulation After Allogeneic Stem Cell Transplantation in AML (NCT02888522) | University Hospital, Caen | 2016-06-01 |
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (NCT02665065) | Actinium Pharmaceuticals | 2016-06-01 |
| Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia (NCT02795520) | OncoTherapy Science, Inc. | 2016-04-01 |
| VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 Years (NCT02606825) | PETHEMA Foundation | 2015-07-01 |
| A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML (NCT02403310) | H. Lee Moffitt Cancer Center and Research Institute | 2015-06-18 |
| A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations (NCT02418000) | Spirita Oncology, LLC | 2015-04-10 |
| Decitabine Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion for Elderly Patients With AML (NCT02662647) | Chinese PLA General Hospital | 2015-04-01 |
| Incidence and Risk Factors for the Development of Invasive Fungal Infection in Patients Diagnosed With Acute Myeloblastic Leukemia (HIFA) (NCT07060612) | Instituto de Investigacion Sanitaria La Fe | 2015-01-01 |
| A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia (NCT02287233) | AbbVie | 2014-12-31 |
| Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia (NCT02221505) | Novartis Pharmaceuticals | 2014-12-01 |
| Photochemotherapy and Graft-versus-leukemia in Acute-leukemia (NCT02631993) | Karolinska University Hospital | 2014-10-01 |
| Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible (NCT02261779) | Martin-Luther-Universität Halle-Wittenberg | 2014-09-01 |
| Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies (NCT02193958) | Fujifilm Pharmaceuticals U.S.A., Inc. | 2014-07-01 |
| Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) (NCT02152956) | MacroGenics | 2014-06-09 |
| (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive (NCT02039726) | Daiichi Sankyo | 2014-05-01 |
| A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) (NCT01994837) | AbbVie | 2013-11-01 |
| Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML） (NCT01690507) | Chinese PLA General Hospital | 2012-11-01 |
| Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients (NCT02575963) | Actinium Pharmaceuticals | 2012-10-01 |
| FLT-PET Imaging for MDS (NCT01535456) | University of Wisconsin, Madison | 2012-07-01 |
| A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors (NCT01449058) | Array BioPharma | 2012-03-01 |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives (NCT01532635) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-03-01 |
| Epidemiologic Registry PETHEMA LMA 2013 (NCT02006004) | PETHEMA Foundation | 2012-01-01 |
| POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients (NCT01319864) | Seattle Children's Hospital | 2011-03-01 |
| Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients (NCT01149408) | University of Utah | 2011-02-01 |
| Rapid Profiling of Bone Marrow, at Presentation and After 5 Days of Induction Therapy (NCT01268800) | Rambam Health Care Campus | 2011-02-01 |
| SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) (NCT01261312) | Astex Pharmaceuticals, Inc. | 2011-01-04 |
| LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) (NCT01198054) | PETHEMA Foundation | 2011-01-01 |
| Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD (NCT03622541) | The University of Hong Kong | 2010-11-15 |
| Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies (NCT01204164) | Tragara Pharmaceuticals, Inc. | 2010-08-01 |
| Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure (NCT01188174) | Nantes University Hospital | 2010-07-01 |
| Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission (NCT01096602) | Beth Israel Deaconess Medical Center | 2010-05-01 |
| A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for Acute Myeloid Leukemia (AML) (NCT00808080) | Thomas A. Lane, MD | 2010-01-01 |
| Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) (NCT01019317) | M.D. Anderson Cancer Center | 2009-11-01 |
| Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT (NCT01012492) | Boston Children's Hospital | 2009-11-01 |
| Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) (NCT00863148) | Nantes University Hospital | 2009-10-01 |
| Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML (NCT00780598) | Chroma Therapeutics | 2009-10-01 |
| A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia (NCT00964873) | Synta Pharmaceuticals Corp. | 2009-08-01 |
| Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) (NCT00887068) | M.D. Anderson Cancer Center | 2009-04-21 |
| STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders (NCT00858572) | Synta Pharmaceuticals Corp. | 2009-03-01 |
| Umbilical Cord Blood Transplant for Hematological Malignancies (NCT00891592) | University of Pennsylvania | 2009-01-01 |
| Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI) (NCT00815568) | Samsung Medical Center | 2008-08-01 |
| Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders (NCT00687414) | Corewell Health West | 2008-04-01 |
| Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML) (NCT00684918) | Gemin X | 2008-04-01 |
| Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant (NCT00684008) | Cytheris, Inc. | 2008-03-01 |
| Phase I Study in RAD 001 Patients With Relapse AML (NCT01074086) | French Innovative Leukemia Organisation | 2008-02-01 |
| Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies (NCT00533078) | Insel Gruppe AG, University Hospital Bern | 2007-11-01 |
| Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) (NCT00542971) | M.D. Anderson Cancer Center | 2007-10-01 |